دورية أكاديمية
أعرض في EDS

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.

التفاصيل البيبلوغرافية
العنوان: Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
المؤلفون: Tesileanu, C Mircea S, Sanson, Marc, Wick, Wolfgang, Brandes, Alba A, Clement, Paul M, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-Francois, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà , Roberta, Weller, Michael, McBain, Catherine, van Linde, Myra E, Aldape, Kenneth, Jenkins, Robert B, Kros, Johan M, Wesseling, Pieter, von Deimling, Andreas, Hoogstrate, Youri, de Heer, Iris, Atmodimedjo, Peggy N, Dubbink, Hendrikus J, Brouwer, Rutger W W, van IJcken, Wilfred F J, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G, Gorlia, Thierry, French, Pim J, van den Bent, Martin J
المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale
المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, no.12, p. 2527-2535 (2022)
سنة النشر: 2022
المجموعة: DIAL@UCL (Université catholique de Louvain)
مصطلحات موضوعية: Antineoplastic Agents, Alkylating, Astrocytoma, Brain Neoplasms, DNA Methylation, DNA Modification Methylases, DNA Repair Enzymes, Dacarbazine, Glioblastoma, Humans, Isocitrate Dehydrogenase, Prospective Studies, Temozolomide
الوصف: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82-1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61-1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1557-3265
العلاقة: boreal:263831; http://hdl.handle.net/2078.1/263831Test; info:pmid/35275197; urn:EISSN:1557-3265
DOI: 10.1158/1078-0432.CCR-21-4283
الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-4283Test
http://hdl.handle.net/2078.1/263831Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.4BC8CA0
قاعدة البيانات: BASE
الوصف
تدمد:15573265
DOI:10.1158/1078-0432.CCR-21-4283